The global market for Genital Herpes Research and Development Pipeline was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Genital Herpes Research and Development Pipeline, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Genital Herpes Research and Development Pipeline by region & country, by Type, and by Application.

The Genital Herpes Research and Development Pipeline market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Genital Herpes Research and Development Pipeline.

Market Segmentation

Scope of Genital Herpes Research and Development Pipeline - Market Report

Report Metric	Details
Report Name	Genital Herpes Research and Development Pipeline - Market
CAGR	5%
Segment by Type:	Acyclovir Aspidasept G-103 GEN-003 GV-2207 HerpeCide-I HSV-529 Pritelivir SB-105A10
Segment by Application	Hospital Clinic
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	AiCuris GmbH & Co. KG, AlphaVax, Inc., Foamix Pharmaceuticals Ltd., Genocea Biosciences, Inc., GenVec, Inc., Immune Design Corp., Immunovaccine, Inc., Mymetics Corporation, NanoBio Corporation, NanoViricides, Inc., PaxVax, Profectus BioSciences, Inc., Sanofi Pasteur SA, Spider Biotech, Starpharma Holdings Limited, Vaccibody AS, Vaxart, Inc., Vical Incorporated.
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Genital Herpes Research and Development Pipeline manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Genital Herpes Research and Development Pipeline in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Genital Herpes Research and Development Pipeline in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

Who are the main players in the Genital Herpes Research and Development Pipeline - Market report?

Ans: The main players in the Genital Herpes Research and Development Pipeline - Market are AiCuris GmbH & Co. KG, AlphaVax, Inc., Foamix Pharmaceuticals Ltd., Genocea Biosciences, Inc., GenVec, Inc., Immune Design Corp., Immunovaccine, Inc., Mymetics Corporation, NanoBio Corporation, NanoViricides, Inc., PaxVax, Profectus BioSciences, Inc., Sanofi Pasteur SA, Spider Biotech, Starpharma Holdings Limited, Vaccibody AS, Vaxart, Inc., Vical Incorporated.

What are the Application segmentation covered in the Genital Herpes Research and Development Pipeline - Market report?

Ans: The Applications covered in the Genital Herpes Research and Development Pipeline - Market report are Hospital, Clinic

What are the Type segmentation covered in the Genital Herpes Research and Development Pipeline - Market report?

Ans: The Types covered in the Genital Herpes Research and Development Pipeline - Market report are Acyclovir, Aspidasept, G-103, GEN-003, GV-2207, HerpeCide-I, HSV-529, Pritelivir, SB-105A10

1 Market Overview

1.1 Genital Herpes Research and Development Pipeline Product Introduction

1.2 Global Genital Herpes Research and Development Pipeline Market Size Forecast

1.3 Genital Herpes Research and Development Pipeline Market Trends & Drivers

1.3.1 Genital Herpes Research and Development Pipeline Industry Trends

1.3.2 Genital Herpes Research and Development Pipeline Market Drivers & Opportunity

1.3.3 Genital Herpes Research and Development Pipeline Market Challenges

1.3.4 Genital Herpes Research and Development Pipeline Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Genital Herpes Research and Development Pipeline Players Revenue Ranking (2023)

2.2 Global Genital Herpes Research and Development Pipeline Revenue by Company (2019-2024)

2.3 Key Companies Genital Herpes Research and Development Pipeline Manufacturing Base Distribution and Headquarters

2.4 Key Companies Genital Herpes Research and Development Pipeline Product Offered

2.5 Key Companies Time to Begin Mass Production of Genital Herpes Research and Development Pipeline

2.6 Genital Herpes Research and Development Pipeline Market Competitive Analysis

2.6.1 Genital Herpes Research and Development Pipeline Market Concentration Rate (2019-2024)

2.6.2 Global 5 and 10 Largest Companies by Genital Herpes Research and Development Pipeline Revenue in 2023

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Genital Herpes Research and Development Pipeline as of 2023)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Acyclovir

3.1.2 Aspidasept

3.1.3 G-103

3.1.4 GEN-003

3.1.5 GV-2207

3.1.6 HerpeCide-I

3.1.7 HSV-529

3.1.8 Pritelivir

3.1.9 SB-105A10

3.2 Global Genital Herpes Research and Development Pipeline Sales Value by Type

3.2.1 Global Genital Herpes Research and Development Pipeline Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Genital Herpes Research and Development Pipeline Sales Value, by Type (2019-2030)

3.2.3 Global Genital Herpes Research and Development Pipeline Sales Value, by Type (%) (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Hospital

4.1.2 Clinic

4.2 Global Genital Herpes Research and Development Pipeline Sales Value by Application

4.2.1 Global Genital Herpes Research and Development Pipeline Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Genital Herpes Research and Development Pipeline Sales Value, by Application (2019-2030)

4.2.3 Global Genital Herpes Research and Development Pipeline Sales Value, by Application (%) (2019-2030)

5 Segmentation by Region

5.1 Global Genital Herpes Research and Development Pipeline Sales Value by Region

5.1.1 Global Genital Herpes Research and Development Pipeline Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Genital Herpes Research and Development Pipeline Sales Value by Region (2019-2024)

5.1.3 Global Genital Herpes Research and Development Pipeline Sales Value by Region (2025-2030)

5.1.4 Global Genital Herpes Research and Development Pipeline Sales Value by Region (%), (2019-2030)

5.2 North America

5.2.1 North America Genital Herpes Research and Development Pipeline Sales Value, 2019-2030

5.2.2 North America Genital Herpes Research and Development Pipeline Sales Value by Country (%), 2023 VS 2030

5.3 Europe

5.3.1 Europe Genital Herpes Research and Development Pipeline Sales Value, 2019-2030

5.3.2 Europe Genital Herpes Research and Development Pipeline Sales Value by Country (%), 2023 VS 2030

5.4 Asia Pacific

5.4.1 Asia Pacific Genital Herpes Research and Development Pipeline Sales Value, 2019-2030

5.4.2 Asia Pacific Genital Herpes Research and Development Pipeline Sales Value by Country (%), 2023 VS 2030

5.5 South America

5.5.1 South America Genital Herpes Research and Development Pipeline Sales Value, 2019-2030

5.5.2 South America Genital Herpes Research and Development Pipeline Sales Value by Country (%), 2023 VS 2030

5.6 Middle East & Africa

5.6.1 Middle East & Africa Genital Herpes Research and Development Pipeline Sales Value, 2019-2030

5.6.2 Middle East & Africa Genital Herpes Research and Development Pipeline Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Genital Herpes Research and Development Pipeline Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Genital Herpes Research and Development Pipeline Sales Value

6.3 United States

6.3.1 United States Genital Herpes Research and Development Pipeline Sales Value, 2019-2030

6.3.2 United States Genital Herpes Research and Development Pipeline Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Genital Herpes Research and Development Pipeline Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Genital Herpes Research and Development Pipeline Sales Value, 2019-2030

6.4.2 Europe Genital Herpes Research and Development Pipeline Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Genital Herpes Research and Development Pipeline Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Genital Herpes Research and Development Pipeline Sales Value, 2019-2030

6.5.2 China Genital Herpes Research and Development Pipeline Sales Value by Type (%), 2023 VS 2030

6.5.3 China Genital Herpes Research and Development Pipeline Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Genital Herpes Research and Development Pipeline Sales Value, 2019-2030

6.6.2 Japan Genital Herpes Research and Development Pipeline Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Genital Herpes Research and Development Pipeline Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Genital Herpes Research and Development Pipeline Sales Value, 2019-2030

6.7.2 South Korea Genital Herpes Research and Development Pipeline Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Genital Herpes Research and Development Pipeline Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Genital Herpes Research and Development Pipeline Sales Value, 2019-2030

6.8.2 Southeast Asia Genital Herpes Research and Development Pipeline Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Genital Herpes Research and Development Pipeline Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Genital Herpes Research and Development Pipeline Sales Value, 2019-2030

6.9.2 India Genital Herpes Research and Development Pipeline Sales Value by Type (%), 2023 VS 2030

6.9.3 India Genital Herpes Research and Development Pipeline Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 AiCuris GmbH & Co. KG

7.1.1 AiCuris GmbH & Co. KG Profile

7.1.2 AiCuris GmbH & Co. KG Main Business

7.1.3 AiCuris GmbH & Co. KG Genital Herpes Research and Development Pipeline Products, Services and Solutions

7.1.4 AiCuris GmbH & Co. KG Genital Herpes Research and Development Pipeline Revenue (US$ Million) & (2019-2024)

7.1.5 AiCuris GmbH & Co. KG Recent Developments

7.2 AlphaVax, Inc.

7.2.1 AlphaVax, Inc. Profile

7.2.2 AlphaVax, Inc. Main Business

7.2.3 AlphaVax, Inc. Genital Herpes Research and Development Pipeline Products, Services and Solutions

7.2.4 AlphaVax, Inc. Genital Herpes Research and Development Pipeline Revenue (US$ Million) & (2019-2024)

7.2.5 AlphaVax, Inc. Recent Developments

7.3 Foamix Pharmaceuticals Ltd.

7.3.1 Foamix Pharmaceuticals Ltd. Profile

7.3.2 Foamix Pharmaceuticals Ltd. Main Business

7.3.3 Foamix Pharmaceuticals Ltd. Genital Herpes Research and Development Pipeline Products, Services and Solutions

7.3.4 Foamix Pharmaceuticals Ltd. Genital Herpes Research and Development Pipeline Revenue (US$ Million) & (2019-2024)

7.3.5 Genocea Biosciences, Inc. Recent Developments

7.4 Genocea Biosciences, Inc.

7.4.1 Genocea Biosciences, Inc. Profile

7.4.2 Genocea Biosciences, Inc. Main Business

7.4.3 Genocea Biosciences, Inc. Genital Herpes Research and Development Pipeline Products, Services and Solutions

7.4.4 Genocea Biosciences, Inc. Genital Herpes Research and Development Pipeline Revenue (US$ Million) & (2019-2024)

7.4.5 Genocea Biosciences, Inc. Recent Developments

7.5 GenVec, Inc.

7.5.1 GenVec, Inc. Profile

7.5.2 GenVec, Inc. Main Business

7.5.3 GenVec, Inc. Genital Herpes Research and Development Pipeline Products, Services and Solutions

7.5.4 GenVec, Inc. Genital Herpes Research and Development Pipeline Revenue (US$ Million) & (2019-2024)

7.5.5 GenVec, Inc. Recent Developments

7.6 Immune Design Corp.

7.6.1 Immune Design Corp. Profile

7.6.2 Immune Design Corp. Main Business

7.6.3 Immune Design Corp. Genital Herpes Research and Development Pipeline Products, Services and Solutions

7.6.4 Immune Design Corp. Genital Herpes Research and Development Pipeline Revenue (US$ Million) & (2019-2024)

7.6.5 Immune Design Corp. Recent Developments

7.7 Immunovaccine, Inc.

7.7.1 Immunovaccine, Inc. Profile

7.7.2 Immunovaccine, Inc. Main Business

7.7.3 Immunovaccine, Inc. Genital Herpes Research and Development Pipeline Products, Services and Solutions

7.7.4 Immunovaccine, Inc. Genital Herpes Research and Development Pipeline Revenue (US$ Million) & (2019-2024)

7.7.5 Immunovaccine, Inc. Recent Developments

7.8 Mymetics Corporation

7.8.1 Mymetics Corporation Profile

7.8.2 Mymetics Corporation Main Business

7.8.3 Mymetics Corporation Genital Herpes Research and Development Pipeline Products, Services and Solutions

7.8.4 Mymetics Corporation Genital Herpes Research and Development Pipeline Revenue (US$ Million) & (2019-2024)

7.8.5 Mymetics Corporation Recent Developments

7.9 NanoBio Corporation

7.9.1 NanoBio Corporation Profile

7.9.2 NanoBio Corporation Main Business

7.9.3 NanoBio Corporation Genital Herpes Research and Development Pipeline Products, Services and Solutions

7.9.4 NanoBio Corporation Genital Herpes Research and Development Pipeline Revenue (US$ Million) & (2019-2024)

7.9.5 NanoBio Corporation Recent Developments

7.10 NanoViricides, Inc.

7.10.1 NanoViricides, Inc. Profile

7.10.2 NanoViricides, Inc. Main Business

7.10.3 NanoViricides, Inc. Genital Herpes Research and Development Pipeline Products, Services and Solutions

7.10.4 NanoViricides, Inc. Genital Herpes Research and Development Pipeline Revenue (US$ Million) & (2019-2024)

7.10.5 NanoViricides, Inc. Recent Developments

7.11 PaxVax

7.11.1 PaxVax Profile

7.11.2 PaxVax Main Business

7.11.3 PaxVax Genital Herpes Research and Development Pipeline Products, Services and Solutions

7.11.4 PaxVax Genital Herpes Research and Development Pipeline Revenue (US$ Million) & (2019-2024)

7.11.5 PaxVax Recent Developments

7.12 Profectus BioSciences, Inc.

7.12.1 Profectus BioSciences, Inc. Profile

7.12.2 Profectus BioSciences, Inc. Main Business

7.12.3 Profectus BioSciences, Inc. Genital Herpes Research and Development Pipeline Products, Services and Solutions

7.12.4 Profectus BioSciences, Inc. Genital Herpes Research and Development Pipeline Revenue (US$ Million) & (2019-2024)

7.12.5 Profectus BioSciences, Inc. Recent Developments

7.13 Sanofi Pasteur SA

7.13.1 Sanofi Pasteur SA Profile

7.13.2 Sanofi Pasteur SA Main Business

7.13.3 Sanofi Pasteur SA Genital Herpes Research and Development Pipeline Products, Services and Solutions

7.13.4 Sanofi Pasteur SA Genital Herpes Research and Development Pipeline Revenue (US$ Million) & (2019-2024)

7.13.5 Sanofi Pasteur SA Recent Developments

7.14 Spider Biotech

7.14.1 Spider Biotech Profile

7.14.2 Spider Biotech Main Business

7.14.3 Spider Biotech Genital Herpes Research and Development Pipeline Products, Services and Solutions

7.14.4 Spider Biotech Genital Herpes Research and Development Pipeline Revenue (US$ Million) & (2019-2024)

7.14.5 Spider Biotech Recent Developments

7.15 Starpharma Holdings Limited

7.15.1 Starpharma Holdings Limited Profile

7.15.2 Starpharma Holdings Limited Main Business

7.15.3 Starpharma Holdings Limited Genital Herpes Research and Development Pipeline Products, Services and Solutions

7.15.4 Starpharma Holdings Limited Genital Herpes Research and Development Pipeline Revenue (US$ Million) & (2019-2024)

7.15.5 Starpharma Holdings Limited Recent Developments

7.16 Vaccibody AS

7.16.1 Vaccibody AS Profile

7.16.2 Vaccibody AS Main Business

7.16.3 Vaccibody AS Genital Herpes Research and Development Pipeline Products, Services and Solutions

7.16.4 Vaccibody AS Genital Herpes Research and Development Pipeline Revenue (US$ Million) & (2019-2024)

7.16.5 Vaccibody AS Recent Developments

7.17 Vaxart, Inc.

7.17.1 Vaxart, Inc. Profile

7.17.2 Vaxart, Inc. Main Business

7.17.3 Vaxart, Inc. Genital Herpes Research and Development Pipeline Products, Services and Solutions

7.17.4 Vaxart, Inc. Genital Herpes Research and Development Pipeline Revenue (US$ Million) & (2019-2024)

7.17.5 Vaxart, Inc. Recent Developments

7.18 Vical Incorporated.

7.18.1 Vical Incorporated. Profile

7.18.2 Vical Incorporated. Main Business

7.18.3 Vical Incorporated. Genital Herpes Research and Development Pipeline Products, Services and Solutions

7.18.4 Vical Incorporated. Genital Herpes Research and Development Pipeline Revenue (US$ Million) & (2019-2024)

7.18.5 Vical Incorporated. Recent Developments

8 Industry Chain Analysis

8.1 Genital Herpes Research and Development Pipeline Industrial Chain

8.2 Genital Herpes Research and Development Pipeline Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Genital Herpes Research and Development Pipeline Sales Model

8.5.2 Sales Channel

8.5.3 Genital Herpes Research and Development Pipeline Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

AlphaVax

Foamix Pharmaceuticals Ltd

Genocea Biosciences Inc

Profectus BioSciences Inc

AiCuris GmbH & Co. KG

Mymetics Corporation

NanoBio Corporation

Spider Biotech

Starpharma Holdings Limited

List of Tables

Table 1. Genital Herpes Research and Development Pipeline Market Trends

Table 2. Genital Herpes Research and Development Pipeline Market Drivers & Opportunity

Table 3. Genital Herpes Research and Development Pipeline Market Challenges

Table 4. Genital Herpes Research and Development Pipeline Market Restraints

Table 5. Global Genital Herpes Research and Development Pipeline Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Genital Herpes Research and Development Pipeline Revenue Market Share by Company (2019-2024)

Table 7. Key Companies Genital Herpes Research and Development Pipeline Manufacturing Base Distribution and Headquarters

Table 8. Key Companies Genital Herpes Research and Development Pipeline Product Type

Table 9. Key Companies Time to Begin Mass Production of Genital Herpes Research and Development Pipeline

Table 10. Global Genital Herpes Research and Development Pipeline Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Genital Herpes Research and Development Pipeline as of 2023)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global Genital Herpes Research and Development Pipeline Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 14. Global Genital Herpes Research and Development Pipeline Sales Value by Type (2019-2024) & (US$ Million)

Table 15. Global Genital Herpes Research and Development Pipeline Sales Value by Type (2025-2030) & (US$ Million)

Table 16. Global Genital Herpes Research and Development Pipeline Sales Market Share in Value by Type (2019-2024) & (%)

Table 17. Global Genital Herpes Research and Development Pipeline Sales Market Share in Value by Type (2025-2030) & (%)

Table 18. Global Genital Herpes Research and Development Pipeline Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 19. Global Genital Herpes Research and Development Pipeline Sales Value by Application (2019-2024) & (US$ Million)

Table 20. Global Genital Herpes Research and Development Pipeline Sales Value by Application (2025-2030) & (US$ Million)

Table 21. Global Genital Herpes Research and Development Pipeline Sales Market Share in Value by Application (2019-2024) & (%)

Table 22. Global Genital Herpes Research and Development Pipeline Sales Market Share in Value by Application (2025-2030) & (%)

Table 23. Global Genital Herpes Research and Development Pipeline Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 24. Global Genital Herpes Research and Development Pipeline Sales Value by Region (2019-2024) & (US$ Million)

Table 25. Global Genital Herpes Research and Development Pipeline Sales Value by Region (2025-2030) & (US$ Million)

Table 26. Global Genital Herpes Research and Development Pipeline Sales Value by Region (2019-2024) & (%)

Table 27. Global Genital Herpes Research and Development Pipeline Sales Value by Region (2025-2030) & (%)

Table 28. Key Countries/Regions Genital Herpes Research and Development Pipeline Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 29. Key Countries/Regions Genital Herpes Research and Development Pipeline Sales Value, (2019-2024) & (US$ Million)

Table 30. Key Countries/Regions Genital Herpes Research and Development Pipeline Sales Value, (2025-2030) & (US$ Million)

Table 31. AiCuris GmbH & Co. KG Basic Information List

Table 32. AiCuris GmbH & Co. KG Description and Business Overview

Table 33. AiCuris GmbH & Co. KG Genital Herpes Research and Development Pipeline Products, Services and Solutions

Table 34. Revenue (US$ Million) in Genital Herpes Research and Development Pipeline Business of AiCuris GmbH & Co. KG (2019-2024)

Table 35. AiCuris GmbH & Co. KG Recent Developments

Table 36. AlphaVax, Inc. Basic Information List

Table 37. AlphaVax, Inc. Description and Business Overview

Table 38. AlphaVax, Inc. Genital Herpes Research and Development Pipeline Products, Services and Solutions

Table 39. Revenue (US$ Million) in Genital Herpes Research and Development Pipeline Business of AlphaVax, Inc. (2019-2024)

Table 40. AlphaVax, Inc. Recent Developments

Table 41. Foamix Pharmaceuticals Ltd. Basic Information List

Table 42. Foamix Pharmaceuticals Ltd. Description and Business Overview

Table 43. Foamix Pharmaceuticals Ltd. Genital Herpes Research and Development Pipeline Products, Services and Solutions

Table 44. Revenue (US$ Million) in Genital Herpes Research and Development Pipeline Business of Foamix Pharmaceuticals Ltd. (2019-2024)

Table 45. Foamix Pharmaceuticals Ltd. Recent Developments

Table 46. Genocea Biosciences, Inc. Basic Information List

Table 47. Genocea Biosciences, Inc. Description and Business Overview

Table 48. Genocea Biosciences, Inc. Genital Herpes Research and Development Pipeline Products, Services and Solutions

Table 49. Revenue (US$ Million) in Genital Herpes Research and Development Pipeline Business of Genocea Biosciences, Inc. (2019-2024)

Table 50. Genocea Biosciences, Inc. Recent Developments

Table 51. GenVec, Inc. Basic Information List

Table 52. GenVec, Inc. Description and Business Overview

Table 53. GenVec, Inc. Genital Herpes Research and Development Pipeline Products, Services and Solutions

Table 54. Revenue (US$ Million) in Genital Herpes Research and Development Pipeline Business of GenVec, Inc. (2019-2024)

Table 55. GenVec, Inc. Recent Developments

Table 56. Immune Design Corp. Basic Information List

Table 57. Immune Design Corp. Description and Business Overview

Table 58. Immune Design Corp. Genital Herpes Research and Development Pipeline Products, Services and Solutions

Table 59. Revenue (US$ Million) in Genital Herpes Research and Development Pipeline Business of Immune Design Corp. (2019-2024)

Table 60. Immune Design Corp. Recent Developments

Table 61. Immunovaccine, Inc. Basic Information List

Table 62. Immunovaccine, Inc. Description and Business Overview

Table 63. Immunovaccine, Inc. Genital Herpes Research and Development Pipeline Products, Services and Solutions

Table 64. Revenue (US$ Million) in Genital Herpes Research and Development Pipeline Business of Immunovaccine, Inc. (2019-2024)

Table 65. Immunovaccine, Inc. Recent Developments

Table 66. Mymetics Corporation Basic Information List

Table 67. Mymetics Corporation Description and Business Overview

Table 68. Mymetics Corporation Genital Herpes Research and Development Pipeline Products, Services and Solutions

Table 69. Revenue (US$ Million) in Genital Herpes Research and Development Pipeline Business of Mymetics Corporation (2019-2024)

Table 70. Mymetics Corporation Recent Developments

Table 71. NanoBio Corporation Basic Information List

Table 72. NanoBio Corporation Description and Business Overview

Table 73. NanoBio Corporation Genital Herpes Research and Development Pipeline Products, Services and Solutions

Table 74. Revenue (US$ Million) in Genital Herpes Research and Development Pipeline Business of NanoBio Corporation (2019-2024)

Table 75. NanoBio Corporation Recent Developments

Table 76. NanoViricides, Inc. Basic Information List

Table 77. NanoViricides, Inc. Description and Business Overview

Table 78. NanoViricides, Inc. Genital Herpes Research and Development Pipeline Products, Services and Solutions

Table 79. Revenue (US$ Million) in Genital Herpes Research and Development Pipeline Business of NanoViricides, Inc. (2019-2024)

Table 80. NanoViricides, Inc. Recent Developments

Table 81. PaxVax Basic Information List

Table 82. PaxVax Description and Business Overview

Table 83. PaxVax Genital Herpes Research and Development Pipeline Products, Services and Solutions

Table 84. Revenue (US$ Million) in Genital Herpes Research and Development Pipeline Business of PaxVax (2019-2024)

Table 85. PaxVax Recent Developments

Table 86. Profectus BioSciences, Inc. Basic Information List

Table 87. Profectus BioSciences, Inc. Description and Business Overview

Table 88. Profectus BioSciences, Inc. Genital Herpes Research and Development Pipeline Products, Services and Solutions

Table 89. Revenue (US$ Million) in Genital Herpes Research and Development Pipeline Business of Profectus BioSciences, Inc. (2019-2024)

Table 90. Profectus BioSciences, Inc. Recent Developments

Table 91. Sanofi Pasteur SA Basic Information List

Table 92. Sanofi Pasteur SA Description and Business Overview

Table 93. Sanofi Pasteur SA Genital Herpes Research and Development Pipeline Products, Services and Solutions

Table 94. Revenue (US$ Million) in Genital Herpes Research and Development Pipeline Business of Sanofi Pasteur SA (2019-2024)

Table 95. Sanofi Pasteur SA Recent Developments

Table 96. Spider Biotech Basic Information List

Table 97. Spider Biotech Description and Business Overview

Table 98. Spider Biotech Genital Herpes Research and Development Pipeline Products, Services and Solutions

Table 99. Revenue (US$ Million) in Genital Herpes Research and Development Pipeline Business of Spider Biotech (2019-2024)

Table 100. Spider Biotech Recent Developments

Table 101. Starpharma Holdings Limited Basic Information List

Table 102. Starpharma Holdings Limited Description and Business Overview

Table 103. Starpharma Holdings Limited Genital Herpes Research and Development Pipeline Products, Services and Solutions

Table 104. Revenue (US$ Million) in Genital Herpes Research and Development Pipeline Business of Starpharma Holdings Limited (2019-2024)

Table 105. Starpharma Holdings Limited Recent Developments

Table 106. Vaccibody AS Basic Information List

Table 107. Vaccibody AS Description and Business Overview

Table 108. Vaccibody AS Genital Herpes Research and Development Pipeline Products, Services and Solutions

Table 109. Revenue (US$ Million) in Genital Herpes Research and Development Pipeline Business of Vaccibody AS (2019-2024)

Table 110. Vaccibody AS Recent Developments

Table 111. Vaxart, Inc. Basic Information List

Table 112. Vaxart, Inc. Description and Business Overview

Table 113. Vaxart, Inc. Genital Herpes Research and Development Pipeline Products, Services and Solutions

Table 114. Revenue (US$ Million) in Genital Herpes Research and Development Pipeline Business of Vaxart, Inc. (2019-2024)

Table 115. Vaxart, Inc. Recent Developments

Table 116. Vical Incorporated. Basic Information List

Table 117. Vical Incorporated. Description and Business Overview

Table 118. Vical Incorporated. Genital Herpes Research and Development Pipeline Products, Services and Solutions

Table 119. Revenue (US$ Million) in Genital Herpes Research and Development Pipeline Business of Vical Incorporated. (2019-2024)

Table 120. Vical Incorporated. Recent Developments

Table 121. Key Raw Materials Lists

Table 122. Raw Materials Key Suppliers Lists

Table 123. Genital Herpes Research and Development Pipeline Downstream Customers

Table 124. Genital Herpes Research and Development Pipeline Distributors List

Table 125. Research Programs/Design for This Report

Table 126. Key Data Information from Secondary Sources

Table 127. Key Data Information from Primary Sources

Table 128. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. Genital Herpes Research and Development Pipeline Product Picture

Figure 2. Global Genital Herpes Research and Development Pipeline Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Genital Herpes Research and Development Pipeline Sales Value (2019-2030) & (US$ Million)

Figure 4. Genital Herpes Research and Development Pipeline Report Years Considered

Figure 5. Global Genital Herpes Research and Development Pipeline Players Revenue Ranking (2023) & (US$ Million)

Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Genital Herpes Research and Development Pipeline Revenue in 2023

Figure 7. Genital Herpes Research and Development Pipeline Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 8. Acyclovir Picture

Figure 9. Aspidasept Picture

Figure 10. G-103 Picture

Figure 11. GEN-003 Picture

Figure 12. GV-2207 Picture

Figure 13. HerpeCide-I Picture

Figure 14. HSV-529 Picture

Figure 15. Pritelivir Picture

Figure 16. SB-105A10 Picture

Figure 17. Global Genital Herpes Research and Development Pipeline Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 18. Global Genital Herpes Research and Development Pipeline Sales Value Market Share by Type, 2023 & 2030

Figure 19. Product Picture of Hospital

Figure 20. Product Picture of Clinic

Figure 21. Global Genital Herpes Research and Development Pipeline Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 22. Global Genital Herpes Research and Development Pipeline Sales Value Market Share by Application, 2023 & 2030

Figure 23. North America Genital Herpes Research and Development Pipeline Sales Value (2019-2030) & (US$ Million)

Figure 24. North America Genital Herpes Research and Development Pipeline Sales Value by Country (%), 2023 VS 2030

Figure 25. Europe Genital Herpes Research and Development Pipeline Sales Value (2019-2030) & (US$ Million)

Figure 26. Europe Genital Herpes Research and Development Pipeline Sales Value by Country (%), 2023 VS 2030

Figure 27. Asia Pacific Genital Herpes Research and Development Pipeline Sales Value (2019-2030) & (US$ Million)

Figure 28. Asia Pacific Genital Herpes Research and Development Pipeline Sales Value by Country (%), 2023 VS 2030

Figure 29. South America Genital Herpes Research and Development Pipeline Sales Value (2019-2030) & (US$ Million)

Figure 30. South America Genital Herpes Research and Development Pipeline Sales Value by Country (%), 2023 VS 2030

Figure 31. Middle East & Africa Genital Herpes Research and Development Pipeline Sales Value (2019-2030) & (US$ Million)

Figure 32. Middle East & Africa Genital Herpes Research and Development Pipeline Sales Value by Country (%), 2023 VS 2030

Figure 33. Key Countries/Regions Genital Herpes Research and Development Pipeline Sales Value (%), (2019-2030)

Figure 34. United States Genital Herpes Research and Development Pipeline Sales Value, (2019-2030) & (US$ Million)

Figure 35. United States Genital Herpes Research and Development Pipeline Sales Value by Type (%), 2023 VS 2030

Figure 36. United States Genital Herpes Research and Development Pipeline Sales Value by Application (%), 2023 VS 2030

Figure 37. Europe Genital Herpes Research and Development Pipeline Sales Value, (2019-2030) & (US$ Million)

Figure 38. Europe Genital Herpes Research and Development Pipeline Sales Value by Type (%), 2023 VS 2030

Figure 39. Europe Genital Herpes Research and Development Pipeline Sales Value by Application (%), 2023 VS 2030

Figure 40. China Genital Herpes Research and Development Pipeline Sales Value, (2019-2030) & (US$ Million)

Figure 41. China Genital Herpes Research and Development Pipeline Sales Value by Type (%), 2023 VS 2030

Figure 42. China Genital Herpes Research and Development Pipeline Sales Value by Application (%), 2023 VS 2030

Figure 43. Japan Genital Herpes Research and Development Pipeline Sales Value, (2019-2030) & (US$ Million)

Figure 44. Japan Genital Herpes Research and Development Pipeline Sales Value by Type (%), 2023 VS 2030

Figure 45. Japan Genital Herpes Research and Development Pipeline Sales Value by Application (%), 2023 VS 2030

Figure 46. South Korea Genital Herpes Research and Development Pipeline Sales Value, (2019-2030) & (US$ Million)

Figure 47. South Korea Genital Herpes Research and Development Pipeline Sales Value by Type (%), 2023 VS 2030

Figure 48. South Korea Genital Herpes Research and Development Pipeline Sales Value by Application (%), 2023 VS 2030

Figure 49. Southeast Asia Genital Herpes Research and Development Pipeline Sales Value, (2019-2030) & (US$ Million)

Figure 50. Southeast Asia Genital Herpes Research and Development Pipeline Sales Value by Type (%), 2023 VS 2030

Figure 51. Southeast Asia Genital Herpes Research and Development Pipeline Sales Value by Application (%), 2023 VS 2030

Figure 52. India Genital Herpes Research and Development Pipeline Sales Value, (2019-2030) & (US$ Million)

Figure 53. India Genital Herpes Research and Development Pipeline Sales Value by Type (%), 2023 VS 2030

Figure 54. India Genital Herpes Research and Development Pipeline Sales Value by Application (%), 2023 VS 2030

Figure 55. Genital Herpes Research and Development Pipeline Industrial Chain

Figure 56. Genital Herpes Research and Development Pipeline Manufacturing Cost Structure

Figure 57. Channels of Distribution (Direct Sales, and Distribution)

Figure 58. Bottom-up and Top-down Approaches for This Report

Figure 59. Data Triangulation

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions